{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:36:35Z","timestamp":1793381795362,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jcjo.2024.05.018","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T20:01:57Z","timestamp":1721505717000},"page":"e38-e51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immune checkpoint inhibitors with or without chemotherapy for orbital, conjunctival, and ocular adnexal squamous cell carcinoma"],"prefix":"10.1016","volume":"60","author":[{"given":"Bita","family":"Esmaeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3531-0933","authenticated-orcid":false,"given":"Janet","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-1066","authenticated-orcid":false,"given":"Hila","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil D.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-0218","authenticated-orcid":false,"given":"Neal","family":"Akhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-7105","authenticated-orcid":false,"given":"Luana Guimaraes","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2024.05.018_bib0001","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0161-6420(99)90161-6","article-title":"Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota","volume":"106","author":"Cook","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0002","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/bjophthalmol-2017-310956","article-title":"Report on the incidence of squamous cell carcinomas affecting the eyelids in England over a 15-year period (2000\u20132014)","volume":"102","author":"Wawrzynski","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0003","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0190-9622(90)70234-9","article-title":"Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987","volume":"23","author":"Gallagher","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0004","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/bjophthalmol-2013-304434","article-title":"Impact of AJCC \u2018T\u2019 designation on risk of regional lymph node metastasis in patients with squamous carcinoma of the eyelid","volume":"98","author":"Nasser","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0005","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.ophtha.2015.04.002","article-title":"Periocular squamous cell carcinoma: TNM staging and recurrence","volume":"122","author":"Sun","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0006","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.ophtha.2004.02.009","article-title":"Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma","volume":"111","author":"Faustina","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/IIO.0b013e3181b7ecd1","article-title":"Squamous cell carcinoma of eyelid, periocular, and periorbital skin","volume":"49","author":"Sullivan","year":"2009","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0008","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jamaophthalmol.2019.0238","article-title":"Validation study of the AJCC cancer staging manual, staging system for eyelid and periocular squamous cell carcinoma","volume":"137","author":"Xu","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clindermatol.2014.10.008","article-title":"Eyelid and ocular surface carcinoma: diagnosis and management","volume":"33","author":"Yin","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0010","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.ophtha.2009.09.031","article-title":"Demographics, etiology, and behavior of conjunctival squamous cell carcinoma in the 21st century","volume":"116","author":"Karcioglu","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0011","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/tmi.12203","article-title":"Epidemiology of ocular surface squamous neoplasia in Africa","volume":"18","author":"Gichuhi","year":"2013","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjc.6600451","article-title":"The epidemiology of conjunctival squamous cell carcinoma in Uganda","volume":"87","author":"Newton","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bjo.83.2.177","article-title":"Conjunctival squamous cell carcinoma in Tanzania","volume":"83","author":"Poole","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0014","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jamaophthalmol.2015.3335","article-title":"Clinical presentation of ocular surface squamous neoplasia in Kenya","volume":"133","author":"Gichuhi","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4103\/2008-322X.194139","article-title":"Prevalence and severity of ocular surface neoplasia in African nations and need for early interventions","volume":"11","author":"Reynolds","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0016","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/IOP.0000000000001798","article-title":"Prognostic factors for orbital exenteration, local recurrence, metastasis, and death from disease in conjunctival squamous cell carcinoma","volume":"37","author":"El-Hadad","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2011.04.001","article-title":"Conjunctival squamous cell carcinoma arising in immunosuppressed patients (organ transplant, human immunodeficiency virus infection)","volume":"118","author":"Shields","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0018","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/IOP.0b013e31829f3a73","article-title":"Multidisciplinary management of lacrimal sac\/nasolacrimal duct carcinomas","volume":"29","author":"El-Sawy","year":"2013","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0019","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3174\/ajnr.A4882","article-title":"Imaging features of malignant lacrimal sac and nasolacrimal duct tumors","volume":"37","author":"Kumar","year":"2016","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/SAP.0000000000002563","article-title":"Surgical and ophthalmologic outcomes of reconstruction in patients treated with eye-sparing surgery and radiation therapy for tumors of the lacrimal drainage apparatus","volume":"86","author":"Olenczak","year":"2021","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0021","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bjophthalmol-2021-319417","article-title":"Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma","volume":"107","author":"Goldfarb","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00000421-199902000-00008","article-title":"Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin","volume":"22","author":"Denic","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0023","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y","article-title":"Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin","volume":"66","author":"Sadek","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0024","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0025","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1001\/archophthalmol.2012.2515","article-title":"Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma","volume":"130","author":"El-Sawy","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0026","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/01.iop.0000202609.92772.c3","article-title":"Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma","volume":"22","author":"Shepler","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0027","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of epidermal growth factor receptor biology","volume":"59.2","author":"Herbst","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0028","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0029","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1200\/JCO.2013.50.3516","article-title":"Epidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapy","volume":"34","author":"Ganesan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IOP.0b013e3182831bf3","article-title":"Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma","volume":"29","author":"Yin","year":"2013","journal-title":"Ophthalmic Plast Recononstr Surg"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0032","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0033","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0034","doi-asserted-by":"crossref","first-page":"v910","DOI":"10.1093\/annonc\/mdz394.071","article-title":"Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III\/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)","volume":"30","author":"Gross","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0035","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0036","article-title":"Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC): an updated analysis","volume":"36","author":"Yushak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0038","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ophtha.2020.09.027","article-title":"Immunotherapy for conjunctival squamous cell carcinoma with orbital extension","volume":"128","author":"Demirci","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0039","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0040","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcjo.2024.05.018_bib0041","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:20:29Z","timestamp":1740381629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418224001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0008418224001662"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.05.018","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors with or without chemotherapy for orbital, conjunctival, and ocular adnexal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}